A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma

Trial Profile

A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Amrubicin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Feb 2016 Results published in the Investigational New Drugs
    • 20 Feb 2016 Primary endpoint (To evaluate the response rate for amrubicin in patients with metastatic or advanced sarcoma as first line therapy) has been met, as per the results published in the Investigational New Drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top